Back to top
more

Omnicell (OMCL)

(Real Time Quote from BATS)

$31.66 USD

31.66
63,910

+0.83 (2.69%)

Updated Aug 12, 2025 11:28 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 245)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Reports Weak Q1 Preliminary Results

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) preliminary first-quarter 2022 results reflect weakness in segments.

Zacks Equity Research

Nevro (NVRO) Stock Falls 19% Despite Q1 Earnings Beat

by Zacks Equity Research

Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q1 partly due to soft domestic performance.

Zacks Equity Research

AMN Healthcare (AMN) Q1 Earnings, Revenues Beat Estimates

by Zacks Equity Research

AMN Healthcare's (AMN) robust Q1 results demonstrate its segmental strength.

Zacks Equity Research

McKesson (MCK) Q4 Earnings Miss, Revenues Beat Estimates

by Zacks Equity Research

McKesson's (MCK) fiscal fourth-quarter 2022 results benefit from segmental growth.

Zacks Equity Research

Inari Medical (NARI) Down 16.9% Despite Q1 Earnings Beat

by Zacks Equity Research

Inari Medical's (NARI) first-quarter results benefit from significant progress made across all of its growth drivers.

Zacks Equity Research

Avanos Medical (AVNS) Q1 Earnings, Revenues Top Estimates

by Zacks Equity Research

Avanos Medical's (AVNS) first-quarter 2022 results reflect strength in the Pain Management segment.

Zacks Equity Research

DaVita (DVA) Misses on Q1 Earnings, Reiterates FY22 EPS View

by Zacks Equity Research

Despite strength in dialysis patient service revenues, DaVita (DVA) records an overall soft Q1 performance.

Zacks Equity Research

CPSI vs. OMCL: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

CPSI vs. OMCL: Which Stock Is the Better Value Option?

Zacks Equity Research

Quidel (QDEL) Q1 Earnings, Revenues Surpass Estimates, Up Y/Y

by Zacks Equity Research

Quidel's (QDEL) robust performance across two of its product categories drives its first-quarter 2022 top line.

Zacks Equity Research

CONMED's (CNMD) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

CONMED's (CNMD) first-quarter earnings reflect strong segmental performance.

Zacks Equity Research

PacBio's (PACB) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

PacBio (PACB) sees strength in Q1 segmental revenues, led by robust consumable and instrument sales.

Zacks Equity Research

LHC Group (LHCG) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

LHC Group's (LHCG) first-quarter results benefit from organic growth in both home health as well as hospice admissions.

Zacks Equity Research

Cardinal Health (CAH) Q3 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Cardinal Health's (CAH) fiscal third-quarter results benefit from a solid performance in the Pharmaceutical segment.

Zacks Equity Research

BD (BDX) Beats on Q2 Earnings and Revenues, Revises FY22 View

by Zacks Equity Research

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal second quarter.

Zacks Equity Research

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Zacks Equity Research

Masimo's (MASI) Q1 Earnings Surpass Estimates, FY22 View Up

by Zacks Equity Research

Masimo's (MASI) robust product shipments drive its Q1 sales.

Zacks Equity Research

Cerner (CERN) Q1 Earnings in Line, Revenues Lag Estimates

by Zacks Equity Research

Cerner's (CERN) first-quarter results benefit from gains across four of its business units.

Zacks Equity Research

PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

PerkinElmer's (PKI) first-quarter results benefit from a solid performance at Discover & Analytics Solutions business.

Zacks Equity Research

AmerisourceBergen (ABC) Q2 Earnings & Revenues Top Estimates

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal second-quarter results benefit from segmental growth.

Zacks Equity Research

Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Robust sales performance across Omnicell's (OMCL) operating segments has contributed to the first-quarter top line.

Zacks Equity Research

Should iShares S&P SmallCap 600 Growth ETF (IJT) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IJT

Zacks Equity Research

Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SLYG

Zacks Equity Research

Omnicell (OMCL) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of 16.90% and 0.70%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should SPDR Portfolio S&P 600 Small Cap ETF (SPSM) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SPSM

Zacks Equity Research

Should Vanguard S&P SmallCap 600 Growth ETF (VIOG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VIOG